Cargando…

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy

Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improves immune reconstitution, resulting in lower nonrel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fabrizio, Vanessa A., Boelens, Jaap Jan, Mauguen, Audrey, Baggott, Christina, Prabhu, Snehit, Egeler, Emily, Mavroukakis, Sharon, Pacenta, Holly, Phillips, Christine L., Rossoff, Jenna, Stefanski, Heather E., Talano, Julie-An, Moskop, Amy, Margossian, Steven P., Verneris, Michael R., Myers, Gary Douglas, Karras, Nicole A., Brown, Patrick A., Qayed, Muna, Hermiston, Michelle, Satwani, Prakash, Krupski, Christa, Keating, Amy K., Wilcox, Rachel, Rabik, Cara A., Chinnabhandar, Vasant, Kunicki, Michael, Goksenin, A. Yasemin, Mackall, Crystal L., Laetsch, Theodore W., Schultz, Liora M., Curran, Kevin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006295/ https://www.ncbi.nlm.nih.gov/pubmed/34788386 http://dx.doi.org/10.1182/bloodadvances.2021006418

Ejemplares similares

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
por: Stefanski, Heather E., et al.
Publicado: (2022)

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
por: Moskop, Amy, et al.
Publicado: (2022)

Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns
por: Barsan, Valentin, et al.
Publicado: (2023)

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL
por: McNerney, Kevin O., et al.
Publicado: (2023)

Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD
por: He, Fiona, et al.
Publicado: (2016)

Mediport use as an acceptable standard for CAR T cell infusion
por: Eylon, Maya, et al.
Publicado: (2023)

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
por: Suryadevara, Carter M., et al.
Publicado: (2018)

DIPG-15. Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T-cells
por: Monje, Michelle, et al.
Publicado: (2022)

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8(+) T cells
por: Gattinoni, Luca, et al.
Publicado: (2005)

Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
por: Nissani, Abraham, et al.
Publicado: (2021)

PTPN22 Acts in a Cell Intrinsic Manner to Restrict the Proliferation and Differentiation of T Cells Following Antibody Lymphodepletion
por: Knipper, Johanna A., et al.
Publicado: (2020)

Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy
por: Schroeder, Brett A, et al.
Publicado: (2020)

Selective CD28 blockade impacts T cell differentiation during homeostatic reconstitution following lymphodepletion
por: Habib, Jakob G., et al.
Publicado: (2023)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

Anti-Gr-1 Antibody Provides Short-Term Depletion of MDSC in Lymphodepleted Mice with Active-Specific Melanoma Therapy
por: Rose, Peter, et al.
Publicado: (2022)

P53. Effect of lymphodepletion and tumour on host and reconstituted regulatory T-cells in a model of murine melanoma
por: Kovács, J, et al.
Publicado: (2014)

Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma
por: Acosta-Medina, Aldo A., et al.
Publicado: (2023)

Convalescent-anti-sars-cov-2-plasma/rituximab/unspecified steroids: Fever and lymphodepletion: 2 case reports
Publicado: (2021)

Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity
por: De Matteis, Serena, et al.
Publicado: (2023)

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
por: Marquard, Franziska, et al.
Publicado: (2023)

3245 Comparison of Health Outcomes in Adolescent and Young Adult (AYA) Oncology Patients Treated at a Pediatric versus Adult Institute
por: Moskop, Amy, et al.
Publicado: (2019)

Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen
por: Guo, Jing, et al.
Publicado: (2022)

EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG
por: Majzner, Robbie, et al.
Publicado: (2021)

Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells
por: Tanaka, Tomohiro, et al.
Publicado: (2017)

Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy
por: Dawicki, Wojciech, et al.
Publicado: (2020)

Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report
por: Liang, Zuyu, et al.
Publicado: (2020)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

A lymphodepleted non‐human primate model for the assessment of acute on‐target and off‐tumor toxicity of human chimeric antigen receptor‐T cells
por: Yagyu, Shigeki, et al.
Publicado: (2021)

FLT3-IRAK dual targeting: an exciting new therapeutic option guided by adaptive activation of immune response pathways
por: Rabik, Cara A., et al.
Publicado: (2020)

Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
por: Wang, Jia, et al.
Publicado: (2020)

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
por: Majzner, Robbie G., et al.
Publicado: (2022)

P1394: RITUXIMAB BASED LYMPHODEPLETION MAY INCREASE ENGRAFTMENT AND EFFICACY OF SECOND INFUSIONS OF CART19 CELLS IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Ortiz-Maldonado, Valentín, et al.
Publicado: (2023)

Handbook of veterinary drugs; a compendium for research and clinical use
por: Rossoff, Irving S.
Publicado: (1974)

SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
por: McNerney, Kevin Owen, et al.
Publicado: (2023)

A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors
por: Li, Dandan, et al.
Publicado: (2023)

2050. Plasma Next-Generation Sequencing for Pathogen Detection in Pediatric Patients at Risk for Invasive Fungal Infection
por: Armstrong, Amy, et al.
Publicado: (2018)

Epstein Barr Virus-Positive Lymphoproliferative Disorder Following Lymphodepletion for MAGE A4 Adoptive Cellular Therapy in a Patient with Synovial Sarcoma: A Case Report
por: Zhou, Maggie, et al.
Publicado: (2023)

Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma
por: Korell, Felix, et al.
Publicado: (2021)

Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis
por: Owen, Kathryn, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hciv6mlpn9qdidgvd0fmga02i3